DPDespoina Papakosta

Despoina Papakosta

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Despoina Papakosta has a total of 110 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Top Cited Papers
    Open Access

    Effect of mepolizumab in airway remodeling in patients with late-onset severe asthma with an eosinophilic phenotype

    by Kalliopi Domvri, Ioanna Tsiouprou, Petros Bakakos, Paschalis Steiropoulos, Konstantinos Katsoulis, Katerina M. Antoniou, Andriana I. Papaioannou, Nikoletta Rovina, Paraskevi Katsaounou, Theodora Papamitsou, et al.


  • Open Access

    Budesonide/formoterol via the Elpenhaler® device in asthmatic patients: A real-world effectiveness study (The BOREAS Study)

    by Petros Bakakos, Despoina Papakosta, Stylianos Loukides

    Introduction: Very limited real-world data have been captured in the Greek asthmatic population regarding the effects of treatment with a fixed-dose combination of budesonide/formoterol via the Elpenhaler® device, on the course of the disease and its impact on the patients’ quality of life...


  • SARS-Cov-2 infection in asthma patients treated with biologics

    by Andriana Papaioannou, Evangelia Fouka, Νikolaos Tzanakis, Katerina Αntoniou, Κonstantinos Samitas, Εleftherios Ζervas, Κonstantinos Κostikas, Κonstantinos Bartziokas, Κonstantinos Porpodis, Despoina Papakosta, et al.

    Background: Viral respiratory infections are associated with asthma exacerbations, still it is uncertain if asthma patients treated with biologics are more vulnerable to SARS-Cov-2 infection. Aim: Evaluation of characteristics and outcomes of COVID-19 disease in asthma patients treated with biologics. Methods: 27 asthma clinics from Greece provided data concerning demographic and functional characteristics, as well as medical treatments of patients treated with biologics. Patients were prospectively followed up and had a PCR test for confirmation of COVID-19 disease in case of suspected symptoms. Results: 541(352 female) patients receiving biologics (omalizumab 210, mepolizumab 321 and benralizumab 9 patients, respectively), mean age 57.3±14.4 years, were studied. In total, 14(2.6%) patients (8 female), mean age 58.6 years had a confirmed SARS-Cov-2 infection. 6/14, all female, were hospitalized due to severe disease, with mean length of hospital stay 15.8 days, while 1 received mechanical ventilation and died from severe COVID-19. Five of PCR+ patients (35.7%) experienced an asthma exacerbation, defined as asthma control deterioration requiring treatment with systemic steroids, while all others had clinical and radiological manifestation of pneumonia without loss of control. Administration of biologics was performed timely, apart from 1 case in which it was delayed according to physician’s decision. Conclusion: Our study confirm that COVID-19 is not more common in asthmatics treated with biologics compared to general population. However, more than a 1/3 experienced an asthma exacerbation, although in the majority infection did not result in loss of control and scheduled administration of biologics was not interrupted.

  • Telomere-Related Gene mutations in a Greek cohort of suspected monogenic pulmonary fibrosis patients

    by Effrosyni D. Manali, Caroline Kannengiesser, Raphael Borie, Ibrahima Ba, Demosthenes Bouros, Vasilios Tzilas, Argyrios Tzouvelekis, Evangelos Bouros, Aikaterini Markopoulou, Katerina Antoniou, et al.

    Background: Telomere-related genes (TRG) mutations are detected in 30% of familial pulmonary fibrosis (FPF) and are also associated with personal/familial extra-pulmonary disease suggestive of short telomere syndrome (STS). Aim: to evaluate the prevalence of TRG mutations in a national cohort of interstitial lung disease (ILD) with suspected genetic predisposition in Greece and to define patients’ characteristics and impact on outcome.Methods: Genetic diagnoses made between December 2014-September 2019 in patients with FPF, pulmonary fibrosis at young age or personal and/or family extra-pulmonary disease suggestive of STS were analyzed. Results: 150 ILD patients, 73% male, age-at-diagnosis 67 years old, 33% non-smokers, 75% with definite/probable UIP or CPFE, 93% with dyspnea/cough, FVC% pred 75%, DLCO% pred 49% were tested; FPF was 65%, 19% young age, 21% personal and 17% family extra-pulmonary disease suggestive of STS; 21% were tested for more than 1 indication. TRG pathogenic variations were detected in 19 (13%): 13 in a familial, 3 in young age and 3 in extra-pulmonary disease suggestive of STS context as follows: TERT, TERC, RTEL1, PARN, NOP10, NHP2 in 8,5,2,2,1 and 1 respectively. No difference was detected in epidemiological-clinical-radiologic-functional characteristics between patients without and with mutations apart from age-at-diagnosis [69 vs 62 years, p<0.001)]. Patients with TRG mutations were deceased at a younger age compared to those without (70 vs 76 years respectively, p=0.045). GAP index was the only independent factor of survival (p=0.029).Conclusion: TRG mutations were detected in 13% of patients tested. TERT and TERC mutations were the most frequent.

  • Mepolizumab in Severe Eosinophilic Asthma: A 2-Year Follow-Up in Specialized Asthma Clinics in Greece: An Interim Analysis

    by Maria Kallieri, Eleftherios Zervas, Konstantinos Katsoulis, Eva Fouka, Konstantinos Porpodis, Konstantinos Samitas, Andriana I. Papaioannou, Maria Kipourou, Eleni Gaki, Stylianos Vittorakis, et al.

    Introduction: Mepolizumab is a monoclonal antibody against IL-5 for the treatment of severe eosinophilic asthma. The aim of the current study was to present a predesigned interim analysis of the data of patients who have completed 1 year of therapy with mepolizumab. Methods: This study is a prospective multicenter, noninterventional 2-year observational study and aims to describe the clinical benefit and safety profile of mepolizumab in patients with severe eosinophilic asthma. Results: Compared to the year preceding the initiation of treatment, the annual rate of exacerbations decreased significantly, from 4.3 ± 2.3 to 1.3 ± 1.8; p < 0.0001. Forty-two patients received maintenance dose of oral corticosteroids (OCS) at baseline. From these patients at the end of 1 year of therapy with mepolizumab, 17 patients (40%) had achieved OCS discontinuation. A reduction in the median dose of OCS was also achieved. After 1 year of treatment with mepolizumab, the asthma control test score significantly increased from 16.3 ± 3.7 to 21.2 ± 3.8 (p < 0.0001). This marked clinical improvement was paralleled by a significant reduction of blood eosinophil count. All patients showed a considerable improvement of airflow limitation. In respect to adverse events of treatment with mepolizumab, 19 patients (27%) were recorded to have at least one such occurrence during their 1-year treatment. Conclusions: We have shown that in patients with severe eosinophilic asthma, 1 year of treatment with mepolizumab was safe, resulted in significant reduction of the annual exacerbation rate, reduction (or even discontinuation) of the needed dose of OCS, and improvements of asthma control and lung function.


  • Lung cancer in patients with Idiopathic Pulmonary Fibrosis. A retrospective multicenter study

    by Theodoros Karampitsakos, Georgia Gomatou, Vasilios Tzilas, Evangelos Bouros, Evangelos Markozannes, Effrosyni Manali, Ioannis Tomos, Katerina Antoniou, Athina Trachalaki, Lykourgos Kolilekas, et al.

    Background: Abundant evidence supports an association between Idiopathic Pulmonary Fibrosis (IPF) and lung cancer development. Data on diagnosis and management of patients with IPF and lung cancer are still scarce. Aim: To estimate prevalence of lung cancer in patients with IPF. Patients and Methods: This was a retrospective multicenter study, enrolling 835 patients with IPF from eight different centers between 2009 and 2018 in Greece. Results: We identified 88 cases of patients with IPF and lung cancer (prevalence=10.5% n=88/835, mean age±SD=71.8±7.1, 82 males, meanFVC±SD= 73.5±18.9, meanDLCO±SD= 45.3±15.6). Six patients (7%) had both lung and other type of cancer. We identified 68 cases (77.3%) of non-small cell lung cancer (32 squamous, 25 adenocarcinoma, 11 non-specified), and 13 cases (14.8%) of small cell lung cancer. An equal distribution of anatomic location of lung cancer between upper and lower lobes was observed. Lung cancer was diagnosed post IPF diagnosis (median latency time=15.9 months) in 68% of patients and synchronously in 29.3% of patients. Chemotherapy was applied in 31.8% of cases, while 33.3% of patients underwent surgery. Median survival of patients with IPF and lung cancer was 27.4 months (95% CI: 20.6 to 36.8). Conclusions: IPF is a risk factor for lung cancer development. Squamous cell carcinoma is the most common histologic subtype in patients with IPF. Large randomized controlled studies on the management of patients with IPF and lung cancer are sorely needed.